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Objectives. The aim of this study was to perform a retrospective
analysis of an institutional experience with a consecutive series of
patients with post–stage I palliation for hypoplastic left heart
syndrome (HLHS).
Background. In a recent review of 212 consecutive patients who
underwent stage I operations for HLHS at our institution between
1983 and 1993, we identified risk factors related to stage I
mortality. We sought to examine the outcome for these patients at
subsequent palliative procedures.
Methods. All patients who underwent stage I reconstruction
between January 1983 and June 1993 and also underwent subse-
quent palliation at our institution were included. Seventy patients
underwent palliative procedures and two underwent heart trans-
plantation. Patient-specific factors and features of the stage II
operation were analyzed for impact on stage II mortality and
actuarial survival.
Results. The only independent risk factor for stage II mortality
was the performance of a nonfenestrated Fontan operation (p <
0.001). There were nine in-hospital deaths (69%) in the 13 patients
undergoing the nonfenestrated Fontan procedure at stage II. Fifty
patients underwent intermediate superior vena cava to pulmonary
artery anastomosis at stage II, with 4 (8%) early deaths. Pulmo-
nary artery augmentation was performed in 19 patients (38%) at
stage II, without increased operative risk. Hypoplastic left heart
syndrome anatomic subtype did not influence stage II mortality.
The modified fenestrated Fontan procedure has been performed
as a third stage in 32 patients whose median age was 28.7 months,
with one early death at a median follow-up of 24.5 months.
Conclusions. A second-stage bidirectional cavopulmonary anas-
tomosis for HLHS reduces second-stage mortality and improves
intermediate survival. The modified fenestrated Fontan operation
may then be performed as a final palliative stage with low
operative risk.
(J Am Coll Cardiol 1997;29:665–70)
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Hypoplastic left heart syndrome (HLHS) is a common congen-
ital heart defect that is responsible for more neonatal deaths in
the United States than any other anomaly (1). Since the first
successful reconstructive palliative procedure was described by
Norwood in 1983 (2), several centers have reported sizeable
clinical series using this approach to HLHS (3–8). The original
surgical strategy proposed by Norwood involved a neonatal
stage I reconstruction, wherein the main pulmonary artery is
connected to the aorta with pulmonary blood flow established
through a systemic to pulmonary shunt, followed by a second-
stage Fontan operation (2). As the high risk nature of the
Fontan operation as a second stage was recognized, the
bidirectional cavopulmonary anastomosis was introduced in
1988 as a second and intermediate stage before completion of
the Fontan operation (9). During the third stage, we currently
undertake a fenestrated Fontan operation (10).
We have previously reported our 10-year institutional re-
sults for stage I palliative reconstruction in a consecutive series
of 212 patients who underwent first-stage palliation between
January 1983 and June 1993 (6). This report summarizes the
results of subsequent palliative reconstructions for this same
consecutive series. Specifically, we sought to identify any
patient- or procedure-specific risk factors related to second-
stage palliation for HLHS. In addition, we sought to examine
the outcome for those patients who have undergone third-
stage modified fenestrated Fontan operations.
Methods
Patients. All patients who underwent stage I reconstruc-
tion at our institution between January 1983 and June 1993
and also underwent subsequent palliative procedures at our
institution were included in this retrospective analysis. There
were 114 stage I operative survivors. Of these, two patients
crossed over to heart transplantation and 70 underwent further
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palliative reconstructions. Patient data were compiled by a
review of clinical records, including operative reports and
preoperative imaging studies. The diagnosis of HLHS was
based on angiographic or two-dimensional echocardiographic
evidence of a diminutive ascending aorta, aortic atresia or
stenosis and a hypoplastic left ventricle. Operative survival was
defined as survival .30 days and the ability to leave the
hospital. Late follow-up was obtained from direct patient
contact or from the patient’s primary cardiologist for 71 of 72
patients during a 1-month period ending February 28, 1995.
This comprised a total of 279 patient years, with a mean
follow-up of 3.4 years and a follow-up range of 0.5 to 8.0 years
from the date of second-stage palliation.
Statistical analysis. Potential risk factors considered for
operative (early) mortality included patient characteristics and
surgical procedures. Rates were compared in contingency table
analyses using the chi-square or Fisher exact test. Dichoto-
mous variables denoted the presence or absence of each
condition. For continuous variables, tests for trend in propor-
tions across quartile categories were performed. Age at stage
II procedure was classified into four categories with cutoff
points at 8 months, 1 year and 2 years of age. Right ventricular
function and tricuspid regurgitation were classified as none/
normal, mild, moderate or severe. Categoric variables such as
anatomic subtype and stage II procedure were tested both with
an overall chi-square test and as dichotomous variables, com-
paring each condition to the rest. Multivariate analysis of stage
II operative mortality with these risk factors was performed
using stepwise logistic regression. For late mortality, survival
time among those who initially survived the procedure was
estimated using Kaplan-Meier curves. Survival estimates ac-
cording to type of stage II procedure were compared using the
log-rank test. All analyses were performed using a standard,
commercially available software package (SAS Institute, Inc.).
Results
Hypoplastic left heart syndrome anatomic subtypes. We
have previously reported the strong influence of anatomic
subtype on both stage I survival and pre–stage II mortality in
our institutional experience (5,6). The significantly better stage
I survival of those patients with mitral stenosis and aortic
stenosis is reflected by the fact that although this group
comprised only 24% of the original cohort, 44% of all stage II
palliative procedures were in patients with mitral stenosis and
aortic stenosis (Fig. 1).
Pre-stage II interim procedures. Post–stage I patients un-
derwent a total of 38 interim operative procedures before stage
II (Table 1). The most frequently performed interim proce-
dure was a tube gastrostomy, which was performed for failure
to thrive in 12 patients. Ten patients underwent balloon
dilation of either the neoaorta or descending thoracic aorta,
and five patients required surgical aortoplasty to treat neoaor-
tic obstruction or persistent coarctation. Four patients under-
went surgical pulmonary artery augmentation, three of whom
also had their Blalock-Taussig shunts enlarged during this
procedure. Three patients required pericardial windows for
persistent hemodynamically significant pericardial effusions.
Stage II procedures. As shown in Table 2, a variety of
second-stage procedures were used during the study period. A
total of 18 patients underwent some form of modified Fontan
procedure. Six patients had a right atrial to pulmonary artery
anastomosis performed with a pulmonary venous to tricuspid
valve baffle. Seven patients underwent the modified Fontan
procedure using the lateral atrial tunnel technique (11,12).
Five patients underwent the lateral atrial tunnel Fontan pro-
cedure with a fenestration of the prosthetic inferior vena cava
to superior vena cava baffle. Beginning in 1988, 50 patients
underwent an intermediate superior vena cava to pulmonary
artery anastomosis in preparation for completion of the Fon-
tan procedure. Forty-seven patients underwent the bidirec-
tional Glenn anastomosis. In seven of these with bilateral
superior vena cavae, bilateral anastomoses were performed.
Figure 1. Distribution of hypoplastic left heart syn-
drome anatomic subtypes in the study cohort at
stage I (left) and stage II palliation (right). AA 5
aortic atresia; AS 5 aortic stenosis; MA 5 mitral
atresia; MS 5 mitral stenosis; Other 5 other ana-
tomic subtypes.
Table 1. Interim Operative Procedures Performed in 38 Stage I
Operative Survivors Before Stage II Operation
Procedure No. of Patients
Gastrostomy 12
Balloon dilation of aorta 10
Aortic patch plasty 5
Pulmonary arterioplasty plus shunt enlargement 3
Pericardial window 3
Pulmonary arterioplasty 1
Additional Blalock-Taussig shunt 1
Enlargement of Blalock-Taussig shunt 1
Tracheostomy 1
Permanent pacemaker 1
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Three patients underwent the hemi-Fontan procedure, where-
in a double superior vena cava to right pulmonary artery
anastomosis was performed and the internal orifice of the
superior vena cava was closed with a prosthetic patch. Two
patients had classic Glenn shunts performed with the place-
ment of left modified Blalock-Taussig shunts, and two patients
underwent orthotopic heart transplantation.
The distribution of the stage II procedure (Fig. 2) shows
that, since the earliest application of the bidirectional cavopul-
monary anastomosis used to treat HLHS at our institution in
1988, this has become our procedure of choice as a second-
stage palliative procedure. The second-stage bidirectional
cavopulmonary connection is typically performed at a much
earlier age than was the modified Fontan operation (Fig. 3).
The bidirectional cavopulmonary anastomosis was performed
at a median age of 8.25 months during the study period.
Twenty-eight concomitant corrective procedures were per-
formed at the time of second-stage palliation (Table 3).
Nineteen patients required pulmonary artery augmentation.
Four patients underwent patch aortoplasty. Two patients had
their pulmonary artery to aorta synthetic tube conduits re-
moved and replaced by a direct pulmonary artery to ascending
aortic anastomosis, augmented by a gusset of pulmonary
homograft. Three patients underwent atrial septectomy for a
restrictive atrial septal defect detected at pre–stage II cathe-
terization.
Stage II mortality. Table 4 summarizes the results of all
stage II procedures performed during the study period. The
early mortality rate for the completed, nonfenestrated modi-
fied Fontan procedure was 69%, with an overall mortality rate
of 77% during the study period. In the 50 patients who
underwent some form of bidirectional cavopulmonary shunt,
there were four operative deaths (8%). Three of these 46
bidirectional cavopulmonary shunt operative survivors died
during follow-up. Two patients died suddenly out of the
hospital, and one patient died during the stage III Fontan
procedure.
Stage II risk factor analysis. Patient-specific anatomic and
physiologic data, as well as procedural features of the stage II
operation, were evaluated as potential risk factors for stage II
operative mortality in both univariate and multivariate analy-
ses (Table 5). Performance of a nonfenestrated Fontan proce-
dure as a stage II procedure, as well as patient age and weight
greater than median, were significant risk factors for stage II
mortality in univariate analysis. Also, a systemic arterial satu-
ration $81% at the time of pre–stage II catheterization
approached significance as a risk factor in univariate analysis
(p 5 0.051). In multivariate analysis using stepwise logistic
regression, the sole independent risk factor for stage II mor-
tality was the performance of a nonfenestrated Fontan proce-
dure, although the power for multivariate analyses was low in
these data.
Post–stage II actuarial survival. Actuarial survival curves
for the three predominant stage II procedures are shown in
Figure 4. Actuarial survival was significantly improved for
patients undergoing a bidirectional cavopulmonary anastomo-
sis as a second-stage procedure (p , 0.001). The actuarial
survival rate at 3 years for all patients undergoing a bidirec-
tional cavopulmonary anastomosis as a second-stage proce-
dure was 86%. The median time to performance of a stage III
fenestrated Fontan operation after stage II procedures was
1.26 years.
Figure 2. Distribution of stage II procedures used
during the study period.
Table 2. Stage II Operations Performed in 72 Patients During
Study Period
Procedure No. of Patients
Fontan 18
RA-PA anastomosis with PV-TV baffle 6
Lateral atrial tunnel 7
Fenestrated lateral atrial tunnel 5
Bidirectional cavopulmonary shunt 50
Bidirectional Glenn 47
Hemi-Fontan 3
Classic Glenn anastomosis with left BTS 2
Orthotopic heart transplantation 2
BTS 5 Blalock-Taussig shunt; PA 5 pulmonary artery; PV 5 pulmonary
venous; RA 5 right atrium; TV 5 tricuspid valve.
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Stage III fenestrated Fontan operation. During the study
period, a total of 52 patients, including the two patients who
had classic Glenn procedures, underwent pre–stage II Fontan
procedures. To date, 32 subsequent fenestrated Fontan proce-
dures have been performed, resulting in one death (3%) from
a presumed ventricular arrhythmia on the day of hospital
discharge. Twenty-five of the 31 stage III Fontan survivors are
presently in New York Heart Association functional class I or
II. Six patients have undergone subsequent transcatheter clo-
sure of the baffle fenestration, and spontaneous closure has
been documented by echocardiography in seven patients. Nine
patients have required subsequent cardiac intervention. In
addition to the six patients undergoing device closure of their
baffle fenestration, two patients have undergone implantation
of permanent pacemakers for sinus node dysfunction, and one
patient has undergone balloon dilation of both pulmonary
arteries.
The systemic arterial oxygen saturations of patients under-
going three-stage palliation are shown in Figure 5. Mean
prehospital discharge saturation after stage I palliation was
75%. After the bidirectional cavopulmonary connection, mean
arterial oxygen saturation increased to 86%. After a stage III
fenestrated Fontan procedure, the mean systemic arterial
oxygen saturation at latest follow-up was 90% for those
patients with a patent fenestration and 96% for those patients
with transcatheter device closure or echocardiographic evi-
dence of spontaneous fenestration closure.
Discussion
Anatomic subtype does not influence outcome for stages II
and III. Although the first successful completion of the Fon-
tan operation for HLHS was performed over a decade ago (2),
the reconstructive approach to this anomaly continues to
challenge clinicians who treat these patients. We have previ-
ously described our results with stage I palliation of HLHS (6).
In that consecutive institutional experience, patients with
atresia of either the mitral or aortic valve were noted to have
higher operative mortality and higher pre–stage II mortality
than patients with mitral stenosis and aortic stenosis. The
present study has demonstrated that HLHS anatomic subtype
does not influence outcome at second- or third-stage opera-
tions.
Staged approach to fenestrated Fontan procedure im-
proves HLHS survival. The addition of the bidirectional cavo-
pulmonary anastomosis as a second stage, before completion
of the fenestrated Fontan operation, has been associated with
improved intermediate survival for stage I operative survivors.
The high early mortality after completion of the stage II
Fontan procedure in this group of patients was attributable to
Figure 3. Age at stage II operation in the study group. Arrow 5 first
hypoplastic left heart syndrome bidirectional cavopulmonary shunt.
Table 3. Concomitant Procedures Performed in 28 Patients at Time
of Stage II Operation
Procedure No. of Patients
PA plasty 19
Aortoplasty 4
Atrial septectomy 3
PA-Ao conduit takedown 2
Ao 5 aorta; PA 5 pulmonary artery.
Table 4. Early and Late Mortality After Stage II Operation
Classified by Type of Stage II Procedure
Stage II Procedure
No. of
Patients
Early
Mortality
Late
Mortality*
Bidirectional Glenn 40 4 (10%) 3 (8%)
Bilateral bidirectional Glenn 7 0 0
Hemi-Fontan 3 0 0
Classic Glenn/BTS 2 0 0
Fenestrated Fontan 5 1 (20%) 1 (25%)
Fontan 13 9 (69%) 1 (25%)
Total 70 14 (20%) 5 (9%)
*Percent among operative survivors. BTS 5 Blalock-Taussig shunt.
Table 5. Stage II Hospital Mortality Risk Factor Analysis
Risk Factor p Value
Gender 0.763
Anatomic subtype 0.123
RV function 0.351
Restrictive ASD 0.947
Stage II procedure type ,0.001
Age 0.007
PVR 0.226
Weight 0.007
Systemic gradient 0.258
Tricuspid regurgitation 0.776
PA plasty 0.454
PA distortion 0.269
Qp/Qs 0.706
SaO2 .81% 0.051
ASD 5 atrial septal defect; PA 5 pulmonary artery; PVR 5 pulmonary
vascular resistance; Qp/Qs 5 total pulmonary blood flow ratio; RV 5 right
ventricular; SaO25 systemic arterial oxygen saturation; Systemic gradient5 right
ventricular outflow, neoaortic arch or descending aortic pressure gradient.
668 FORBESS ET AL. JACC Vol. 29, No. 3
SECOND- AND THIRD-STAGE PROCEDURES FOR HLHS March 1, 1997:665–70
a progressively low cardiac output during the early postoper-
ative period (13–15).
We have performed the fenestrated Fontan operation as a
third-stage procedure in this group with low operative risk,
stable intermediate survival and good intermediate cardiac
functional outcome in most patients. These data are in agree-
ment with those of Jacobs and Norwood (16), who have
reported improved results with staging toward the Fontan
operation and improved Fontan results using baffle fenestra-
tion.
The theoretic considerations, which these data support, for
this operative sequence have been discussed previously
(4,9,17–21). The major beneficial contribution of the bidirec-
tional cavopulmonary anastomosis to stage I anatomy is the
removal of the excess ventricular volume loading inherent in
arterial shunt-dependent single ventricle physiology. The ma-
jority of stage I survivors in this series received a 3.5-mm
modified Blalock-Taussig shunt. At the time of pre–stage II
evaluation, these growing patients were usually demonstrating
increased cyanosis from inadequate shunt flow. For this rea-
son, we also noted an increase in mean arterial saturation after
the stage II bidirectional cavopulmonary anastomosis (Fig. 5).
Fontan circulation versus cardiac allotransplantation for
HLHS. Some investigators have expressed concern about the
long-term outcome for patients with a Fontan circulation
versus those with a biventricular circulation (22–24). This has
led some to advocate cardiac allotransplantation for neonates
with HLHS (25–27). This approach is limited by inadequate
numbers of appropriate organ donors (28), however, and the
unknown effects of lifelong immunosuppression. In our HLHS
patients with Fontan anatomy, we observed stable ventricular
performance and cardiac functional status over the time frame
analyzed. Cardiac interventions unrelated to fenestration clo-
sure have been the exception rather than the rule.
Factors potentially influencing composition of the study
group. We have previously reported increased stage I mortal-
ity and pre–stage II attrition in these patients with HLHS with
either mitral or aortic atresia compared with patients with
mitral stenosis and aortic stenosis (6). We have speculated that
this difference may be the result of technical variations in stage
I procedure types used for these anatomic variants. We have
presently standardized our stage I operation to what we have
previously labeled a type 1 procedure, wherein the ascending
aorta is anastomosed in a side to side fashion to the divided
Figure 4. Actuarial survival according to type of
stage II operation used. BDG5 bidirectional Glenn
anastomosis.
Figure 5. Room air systemic arterial oxygen satura-
tion (SaO2) throughout the three-stage palliative
sequence. Stage I 5 predischarge after stage I oper-
ation; Pre II5 at cardiac catheterization before stage
II operation; Stage II 5 predischarge after stage II
operation; Pre III 5 at cardiac catheterization before
stage III modified fenestrated Fontan operation; Post
III 5 at latest follow-up after stage III modified
fenestrated Fontan operation.
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main pulmonary artery and the neoaortic arch is augmented
using a homograft gusset (6). Additional analysis of a current
cohort of patients would be required to determine if anatomic
subtype continues to influence pre–stage II attrition for stage I
survivors, since this standardization.
Clearly the pre–stage II attrition for stage I survivors of all
anatomic subtypes has decreased. During the second half of
this study period, 85% of all stage I hospital survivors have
undergone subsequent second-stage operation (6). We are
encouraged by these results and continue to offer staged
reconstruction to all patients with HLHS who are ade-
quately resuscitated, have satisfactory ventricular function
and do not have additional severe congenital anomalies.
Only continued follow-up of these patients with Fontan
anatomy will reveal the long-term outcome for this treat-
ment strategy for HLHS.
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